FLINT, Mich., Nov. 21, 2016 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is now filling prescriptions for CUVITRU™ (immune globulin subcutaneous [human], 20 percent solution), which was recently approved by the Food and Drug Administration. CUVITRU is indicated as a replacement therapy for primary humoral immunodeficiency in adult and pediatric patients 2 years and older.
To learn more about Diplomat's immune globulin program, click here.
"We are excited to offer patients a therapy that expands their options for treating primary immunodeficiency," said Paul Urick, Diplomat's president. "CUVITRU is an important treatment for patients with unmet needs."
There are more than 300 primary immunodeficiency disorders, in which part of the body's immune system is missing or does not function properly. Normally, the immune system protects the body from pathogenic microorganisms like bacteria, viruses, and fungi, which can cause infectious diseases. When any part of a person's immune system is absent or dysfunctional, that person is susceptible to and may take longer to recover from infections.
CUVITRU is a ready-to-use injection solution administered via subcutaneous infusion only.
CUVITRU is manufactured by Shire. Click here for full prescribing information.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2015, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is.
Kali Lucas, Public Relations Specialist
810.768.9580 | [email protected]
Gary Rice, RPh, MS, MBA, CSP,
Executive Vice President of Operations
810.768.9863 | [email protected]
SOURCE Diplomat Pharmacy, Inc.